Nov 9 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS IMPROVED AND STATISTICALLY SIGNIFICANT SURVIVAL BENEFIT FOR THREE KEY PATIENT GROUPS IN FINAL PHASE IIB AIPAC STUDY RESULTS IN METASTATIC BREAST CANCER
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.3¢ |
Change
0.023(5.36%) |
Mkt cap ! $523.0M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.3¢ | 42.0¢ | $583.6K | 1.360M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 16344 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 91763 | 17 |
View Market Depth
| Last trade - 13.52pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
0.023 ( 4.34 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 44.0¢ | 42.0¢ | 430062 | ||
| Last updated 13.58pm 29/04/2024 ? | |||||
| IMM (ASX) Chart |